Cranberry product versus low dose trimethoprim in the prevention of recurrent urinary infections in older women: a double blind randomised trial of effectiveness and acceptability

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
01/06/2006		☐ Protocol		
Registration date 13/06/2006	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
21/02/2018	Urological and Genital Diseases			

Plain English summary of protocol

Background and study aims

Recent evidence shows that substances found in cranberries might help in preventing recurrent urinary infections. Recurrent urinary infections are common and troubling in older women. The usual treatment is either repeated doses of antibiotic at the time of infection or continuous low doses of antibiotic for prolonged periods of time. Unfortunately antibiotics have unwanted effects and may harm the good bacteria of your gut and lead to the development of antibiotic resistant infections.

The aim of this study is to find out whether cranberry products will reduce the occurrence of urinary infections when compared to the usual treatment with low doses of trimethoprim (an antibiotic).

Who can participate?

Adult women aged 45 years or over who have had two UTIS or episodes of cystitis in the previous 12 months

What does the study involve?

The study lasts for 6 months. At the start, participants provide a sample of urine. They are randomly allocated to one of two groups. All participants take one capsule of study medication each day, which will contain either 100mg of trimethoprim, or 500mg of cranberry extract depending on their group.

During the 6 months in the study, participants are asked to report any urine infections you have, any courses of antibiotics you take, and any side effects that you experience. At the end of the 6 months, any spare study capsules that are left will be taken back and counted.

What are the possible benefits and risks of participating?

It is possible that participants will have fewer urine infections as a result of taking one of the

study medications, but we do not know which one will prevent more infections. There are no known side effects of cranberry product. Trimethoprim, a commonly used antibiotic, is the recommended treatment for urinary infections, but it can rarely cause side effects like upset stomach and rashes.

Where is the study run from? Ninewells Hospital Dundee (UK)

When is the study starting and how long is it expected to run for? September 2006 to August 2008

Who is funding the study? Moulton Charitable Foundation (UK)

Who is the main contact?
Prof Marion McMurdo (Scientific)

Contact information

Type(s)

Scientific

Contact name

Prof Marion McMurdo

Contact details

Ageing and Health Division of Medicine and Therapeutics Ninewells Hospital and Medical School Dundee United Kingdom DD1 9SY

Additional identifiers

EudraCT/CTIS number 2006-001313-15

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers 555555

Study information

Scientific Title

Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women

Study objectives

- 1. What is the relative effectiveness of low dose trimethoprim compared to cranberry product in the prevention of urinary tract infections in older women with recurrent infections?
- 2. What is the acceptability of and adherence to both preventative treatments?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Tayside Committee of Medical Research Ethics, 23/03/2006, ref: 06/S1402/23

Study design

Double-blind, randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Prevention

Participant information sheet

Health condition(s) or problem(s) studied

Recurrent urinary tract infections

Interventions

Trimethoprim 100 mg daily versus 500 mg cranberry product daily

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Trimethoprim

Primary outcome measure

Current primary outcome measure (as of 21/02/2018:)

First recurrence of symptomatic urinary tract infection self reported by patient during 6 month study

Previous primary outcome measure:

First recurrence of symptomatic urinary tract infection

Secondary outcome measures

Current secondary outcome measures (as of 21/02/2018):

Acceptability and adherence, measured by number of capsules left at the end of the 6 month study

Previous secondary outcome measure:

Acceptability and adherence

Overall study start date

01/09/2006

Completion date

31/08/2008

Eligibility

Key inclusion criteria

Community dwelling women aged 45 years or over with at least two antibiotic-treated urinary tract infections or episodes of cystitis in the previous 12 months

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

120

Key exclusion criteria

- 1. Previous urological surgery, stone or anatomical abnormalities
- 2. Urinary catheter
- 3. Diabetes mellitus
- 4. Immunocompromised
- 5. Pyelonephritis
- 6. Severe renal impairment
- 7. Blood dyscrasia
- 8. Symptomatic urinary tract infection (UTI) at baseline
- 9. Cognitive impairment precluding informed consent
- 10. Resident in institutional care
- 11. On longterm antibiotics
- 12. On warfarin therapy
- 13. Regular cranberry consumers
- 14. Unwilling to participate

Date of first enrolment

01/09/2006

Date of final enrolment

31/08/2008

Locations

Countries of recruitment

Scotland

United Kingdom

Study participating centre Ageing and Health

Dundee United Kingdom DD1 9SY

Sponsor information

Organisation

University of Dundee (UK)

Sponsor details

Research and Innovation Services University of Dundee Dundee Scotland United Kingdom DD1 4HN

Sponsor type

University/education

ROR

https://ror.org/03h2bxq36

Funder(s)

Funder type

Charity

Funder Name

Results and Publications

Publication and dissemination plan

Intention to publish date

Individual participant data (IPD) sharing plan

Individual participant data are not available for sharing

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2009		Yes	No
Basic results		21/02/2018	21/02/2018	No	No